In a post hoc analysis of nearly 1,900 adults with type 2 diabetes, tirzepatide at all doses helped more patients simultaneously achieve targets for blood sugar, weight loss, blood pressure, and lipids compared to semaglutide.
57% vs 34%Tirzepatide 15 mg helped 57% of patients achieve three or more standard therapeutic targets at 40 weeks, compared to 34% on semaglutide 1 mg
What the researchers found
All three doses of tirzepatide (5, 10, and 15 mg) outperformed semaglutide 1 mg in helping patients achieve multiple standard and intensive therapeutic targets simultaneously at 40 weeks.
For standard targets, 57% of patients on tirzepatide 15 mg met three or more goals versus 34% on semaglutide. For intensive targets, the gap was even wider: 29% on tirzepatide 15 mg versus 8% on semaglutide achieved three or more goals.
Tirzepatide significantly increased the odds of achieving both standard and intensive weight loss targets (>10% weight loss: OR 2.72; >15% weight loss: OR 3.86) and intensive blood pressure targets (OR 1.45). Tirzepatide also improved HbA1c target attainment across both standard and intensive thresholds.
Why it matters
Most diabetes management focuses on individual targets like blood sugar. But patients who simultaneously control HbA1c, weight, blood pressure, and cholesterol have far better long-term outcomes. This analysis shows tirzepatide's dual GLP-1/GIP mechanism provides a meaningful advantage over semaglutide across multiple metabolic dimensions — not just one — which could translate to better prevention of diabetes complications.
How the study worked
This was a post hoc analysis of the SURPASS-2 trial, a randomized phase 3 study of 1,879 adults with type 2 diabetes. Participants had been randomized to tirzepatide (5, 10, or 15 mg weekly) or semaglutide (1 mg weekly). Researchers compared the proportion of patients meeting standard and intensive therapeutic targets for HbA1c, weight loss, blood pressure, and lipid profile at 40 weeks. Data was accessed through the Vivli clinical research data platform.
What this study cannot tell us
This is a post hoc analysis, not a pre-specified endpoint of the original trial, which limits the strength of causal conclusions. The comparison used semaglutide 1 mg, not the higher 2.4 mg dose approved for weight management. The 40-week timeframe may not capture long-term differences in cardiovascular outcomes or complications. The original SURPASS-2 trial population may not represent all type 2 diabetes patients.
How to read the evidence
This is a post hoc analysis of a large, well-designed randomized phase 3 trial (SURPASS-2). While the original trial provides high-quality evidence, post hoc analyses are hypothesis-generating rather than confirmatory. The large sample size and clear dose-response relationship strengthen the findings.
When this study was published
Published in 2025, this analysis is highly current and directly relevant to one of the most active areas of clinical debate — how tirzepatide and semaglutide compare for comprehensive diabetes management.
The bigger picture
As GLP-1-based therapies dominate the diabetes and obesity treatment landscape, head-to-head comparisons between tirzepatide and semaglutide are critical for guiding clinical decisions. This analysis adds evidence that tirzepatide's dual-agonist approach provides broader metabolic benefits. However, real-world factors like cost, availability, side effects, and long-term outcomes data will ultimately determine which drug is best for each patient.
Questions still open
- Would tirzepatide maintain its superiority over the higher 2.4 mg dose of semaglutide used for obesity treatment?
- Do these improvements in hitting multiple therapeutic targets translate into fewer cardiovascular events and diabetes complications over years?
- How do cost-effectiveness and side effect profiles factor into the clinical choice between tirzepatide and semaglutide?
Common questions
How did tirzepatide compare to semaglutide for weight loss specifically?
Does this mean tirzepatide is better than semaglutide for everyone with type 2 diabetes?
Read the original research
Efficacy of tirzepatide versus semaglutide in achieving therapeutic targets in type 2 diabetes: a post hoc analysis of the SURPASS-2 Trial.
Diabetologia
Citation
Neves, João Sérgio; Leite, Ana Rita; Vale, Catarina; Marques, Pedro; Vasques-Nóvoa, Francisco; Leite-Moreira, Adelino; Ferreira, João Pedro. (2025). Efficacy of tirzepatide versus semaglutide in achieving therapeutic targets in type 2 diabetes: a post hoc analysis of the SURPASS-2 Trial.. Diabetologia. https://doi.org/10.1007/s00125-025-06637-7